kabutan

Noile-Immune Biotech, The Current Fiscal Year's Undisclosed Net Income to Narrow

Thu Nov 13, 2025 3:30 pm JST Earnings

4893 Noile-Immune Biotech Inc. 【J-GAAP】

Earnings Report

Noile-Immune Biotech Inc. <4893> [TSE Growth] announced its financial results after the market closed on November 13th (15:30). The net loss (non-consolidated) for the cumulative third quarter of the fiscal year ending December 2025 (January to September) was a reduced loss of 605 million yen (compared to a loss of 787 million yen in the same period last year).

In addition, the full-year forecast, which was not disclosed, shows that net loss further decrease to loss of 809 million yen (compared to a loss of 964 million yen in the previous period).

Based on the cumulative third-quarter performance announced by the company and the full-year plan, our calculation indicates that the net loss for the October to December period (4Q) is expected to expand to a loss of 204 million yen (compared to a loss of 177 million yen in the same period last year).

In the most recent three-month period, from July to September (3Q), the net loss expanded to a loss of 194 million yen (compared to a loss of 104 million yen in the same period last year). The operating profit/loss margin drastically worsened from -7033.3% in the same period last year to -19600.0%.

Kabutan News

Actual Results

Accumulated Results 3rd Quarter
Fiscal Year Revenue Operating Profit Ordinary Profit Net Profit Adj. EPS Progress Rate vs. First Half Announce Accounting Standards
Jan - Sep, 2023 314 -495 -848 -850 -20.8 ー Nov 13, 2023 J-GAAP
Jan - Sep, 2024 5 -892 -785 -787 -18.2 ー Nov 14, 2024 J-GAAP
Jan - Sep, 2025 5 -608 -602 -605 -14.0 ー Nov 13, 2025 J-GAAP
YoY 0.0% +31.8% +23.3% +23.1% +23.2%

Guidance Update

Second Half Update

Fiscal Year Revenue Operating Profit Ordinary Profit Net Profit Adj. EPS Adj. Dividend Announce Accounting Standards
Jul - Dec, 2025 Prev ー ー ー ー － 0 Feb 14, 2025 J-GAAP
Jul - Dec, 2025 New 1 -400 -396 -398 -9.2 0 Nov 13, 2025 J-GAAP
Revision Rate － － － － －

Full Year Update

Fiscal Year Revenue Operating Profit Ordinary Profit Net Profit Adj. EPS Adj. Dividend Announce Accounting Standards
Dec, 2025 Prev ー ー ー ー － 0 Feb 14, 2025 J-GAAP
Dec, 2025 New 5 -812 -806 -809 -18.7 0 Nov 13, 2025 J-GAAP
Revision Rate － － － － －

Current Period Guidance

Second Half Results

Fiscal Year Revenue Operating Profit Ordinary Profit Net Profit Adj. EPS Adj. Dividend Announce Accounting Standards
Jul - Dec, 2024 5 -388 -280 -281 -6.5 0 Feb 14, 2025 J-GAAP
Jul - Dec, 2025 Guidance 1 -400 -396 -398 -9.2 0 Nov 13, 2025 J-GAAP
YoY -80.0% -3.1% -41.4% -41.6% -41.6%

Current Period Guidance

Fiscal Year Revenue Operating Profit Ordinary Profit Net Profit Adj. EPS Adj. Dividend Announce Accounting Standards
Dec, 2023 316 -775 -1,127 -1,130 -27.3 0 Feb 13, 2024 J-GAAP
Dec, 2024 7 -1,069 -962 -964 -22.3 0 Feb 14, 2025 J-GAAP
Dec, 2025 Guidance 5 -812 -806 -809 -18.7 0 Nov 13, 2025 J-GAAP
YoY -28.6% +24.0% +16.2% +16.1% +16.2%

Quarterly Results

Fiscal Year Revenue Operating Profit Ordinary Profit Net Profit Adj. EPS Operating Profit Margin Announce Accounting Standards
Jul - Sep, 2024 3 -211 -103 -104 -2.4 -7,033.3 Nov 14, 2024 J-GAAP
Oct - Dec, 2024 2 -177 -177 -177 -4.1 -8,850.0 Feb 14, 2025 J-GAAP
Jan - Mar, 2025 2 -241 -239 -240 -5.6 -12,050.0 May 12, 2025 J-GAAP
Apr - Jun, 2025 2 -171 -171 -171 -4.0 -8,550.0 Aug 8, 2025 J-GAAP
Jul - Sep, 2025 1 -196 -192 -194 -4.5 -19,600.0 Nov 13, 2025 J-GAAP
YoY -66.7% +7.1% -86.4% -86.5% -86.7%

Related Articles